| Ytd | -33.68% | |
| 1y | 47.13% |
| Open | 1.28 | Prev Close | 1.25 | Low | 1.24 | High | 1.30 | Mkt Cap | 82.31M |
| Vol | 445.36K | Avg Vol | 806.94K | EPS | -0.32 | P/E | N/A | Forward P/E | -1.44 |
| Beta | 1.29 | Short Ratio | 1.92 | Inst. Own | 31.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-22 | 50-d Avg | 1.38 | 200-d Avg | 1.85 | 1yr Est | 3.60 |
IBIO News
Squarepoint Ops LLC acquired a new stake in iBio, Inc. (NASDAQ: IBIO) during the undefined quarter,
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN ra
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnol
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnolo
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnolo
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to pr
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announ
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypert
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate u
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primate
iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are b
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of pr
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-ca
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Prog
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in
Vincerx Pharma (NASDAQ: VINC - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both sma
Shares of iBio, Inc. (NYSEMKT:IBIO - Get Free Report) traded up 8.3% during trading on Friday. The s
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of pre
